JP2022518733A5 - - Google Patents

Info

Publication number
JP2022518733A5
JP2022518733A5 JP2021542102A JP2021542102A JP2022518733A5 JP 2022518733 A5 JP2022518733 A5 JP 2022518733A5 JP 2021542102 A JP2021542102 A JP 2021542102A JP 2021542102 A JP2021542102 A JP 2021542102A JP 2022518733 A5 JP2022518733 A5 JP 2022518733A5
Authority
JP
Japan
Prior art keywords
patient
migalastat
salt
cbv
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021542102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518733A (ja
JP7680356B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014531 external-priority patent/WO2020154354A1/en
Publication of JP2022518733A publication Critical patent/JP2022518733A/ja
Publication of JP2022518733A5 publication Critical patent/JP2022518733A5/ja
Priority to JP2025077689A priority Critical patent/JP2025128105A/ja
Application granted granted Critical
Publication of JP7680356B2 publication Critical patent/JP7680356B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021542102A 2019-01-22 2020-01-22 ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用 Active JP7680356B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077689A JP2025128105A (ja) 2019-01-22 2025-05-08 ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795524P 2019-01-22 2019-01-22
US62/795,524 2019-01-22
PCT/US2020/014531 WO2020154354A1 (en) 2019-01-22 2020-01-22 Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077689A Division JP2025128105A (ja) 2019-01-22 2025-05-08 ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用

Publications (3)

Publication Number Publication Date
JP2022518733A JP2022518733A (ja) 2022-03-16
JP2022518733A5 true JP2022518733A5 (https=) 2023-01-30
JP7680356B2 JP7680356B2 (ja) 2025-05-20

Family

ID=69726736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021542102A Active JP7680356B2 (ja) 2019-01-22 2020-01-22 ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
JP2025077689A Pending JP2025128105A (ja) 2019-01-22 2025-05-08 ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077689A Pending JP2025128105A (ja) 2019-01-22 2025-05-08 ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用

Country Status (17)

Country Link
US (1) US20220087993A1 (https=)
EP (2) EP4523750A3 (https=)
JP (2) JP7680356B2 (https=)
AR (1) AR117861A1 (https=)
DK (1) DK3914247T3 (https=)
ES (1) ES3007212T3 (https=)
FI (1) FI3914247T3 (https=)
HR (1) HRP20250078T1 (https=)
HU (1) HUE069934T2 (https=)
LT (1) LT3914247T (https=)
PL (1) PL3914247T3 (https=)
PT (1) PT3914247T (https=)
RS (1) RS66410B1 (https=)
SI (1) SI3914247T1 (https=)
SM (1) SMT202500034T1 (https=)
TW (1) TW202042812A (https=)
WO (1) WO2020154354A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594268B2 (en) * 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
TW202408513A (zh) * 2016-07-19 2024-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症

Similar Documents

Publication Publication Date Title
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
EP0397831A1 (en) Treatment of obesity.
JP2009511618A (ja) 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用
PT1007053E (pt) Tratamento da dor
JP2020531550A5 (https=)
SK14612003A3 (sk) Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu
AU2022202218A1 (en) Combination Therapy Using Acamprosate And D-Cycloserine
EP1572206B1 (en) Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
US5753712A (en) Treatment of migraine headaches and formulations
JP2017533211A5 (https=)
CA2403994C (en) Nasal administration of agents for the treatment of gastroparesis
JP2022518733A5 (https=)
EP4415701A1 (en) Method of administering oxybate
US20080311196A1 (en) All Day Rhinitic Condition Treatment Regimen
JPH037218A (ja) 薬剤組成物
EP2830605B1 (en) A combination medicament comprising phenylephrine and paracetamol
FI3914247T3 (fi) Migalostaatin käyttö alennettaessa aivoverisuonitapahtuman riskiä potilaissa, joilla on fabryn tauti
WO1995022324A1 (en) Treatment of migraine headaches and formulations
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
JP2024525760A5 (https=)
US20170087104A1 (en) Medicament
CN1165306C (zh) 抗感冒的复方药物组合物
KR20010052895A (ko) 치료 방법
AU2023222825A1 (en) Medication
BR112021007839A2 (pt) tratamento e prevenção de ejaculação prematura (ep)